Diseases & Conditions
Grants & Contracts
News & Events
The aerobiology section at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) develops aerosol animal models of disease caused by high-consequence pathogens within animal biosafety level 4 (ABSL-4) containment laboratories.
Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.
The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.
The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories.
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
The core services group at the Integrated Research Facility at Fort Detrick (IRF Frederick) provides cell culture, hematology, hemostasis, clinical chemistry, microbiology, and molecular virology support for monitoring animals in infectious disease studies.
The drug screening team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) can test and characterize the antiviral activity of novel compounds, drugs, and antibodies against multiple viruses in multiple cell lines under a variety of conditions.
The electron microscopy laboratory at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has a variety of capabilities for the analysis of biological samples at an ultrastructural level.
The GCID use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes. Multiple strains and isolates of specific microbial species, populations and communities have been and continue to be sequenced.
In vivo imaging is gaining increasing interest for the characterization of infectious diseases, including the ones caused by high-consequence pathogens.
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
The ICSSC provides a wide range of support services to clinical investigators who are conducting international research funded by the Division of Microbiology and Infectious Diseases (DMID), including consultation and assistance to investigators for protocol development, site assessment, data man
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
The Orfeome Project is part of the NIAID-supported Functional Genomics Program.
The primary objective of the Clinical Studies Support Team (CSST) is to develop and foster overseas relationships through the support of research studies and clinical trials.
PathogenAR is an Augmented Reality application from the National Institute for Allergy and Infectious Diseases (NIAID). Explore interactive stories about pathogens and pathogenic disease using touch gestures or a Merge Cube Device.
The pathology and histology laboratories at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) work together to conduct comprehensive postmortem examinations on laboratory animals of a variety of species studied as models for high-consequence emerging human viral infections.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo